Cognitive assessment of patients with Parkinson’s disease
Keywords:
Estilos de afrontamiento, Psicocardiología, Rehabilitación CardiovascularAbstract
Introduction: In Ecuador, in recent years, there has been an increase in the prevalence of PD and a longer life expectancy among patients. This calls for the generation of updated evidence on the relationship between cognitive status and the severity of Parkinson's disease, aspects that have been poorly explored in this population.
Objective: To determine the relationship between the cognitive status of patients and the severity of Parkinson's disease, as well as the association with sociodemographic and clinical variables.
Material and Methods: A descriptive, cross-sectional observational study was carried out on a sample of 29 patients with Parkinson's disease sequentially selected from those who attended the Neurology service of General District Hospital “Pablo Arturo Suárez” in the time interval from February to November 2023.
Results: Cognitive impairment predominated in 75.9% of patients with Parkinson's, with the most affected functions being verbal memory (51.5%), verbal fluency (51.7%) and cognitive flexibility (57.7%). Furthermore, the analysis did not find a statistically significant relationship between disease severity and cognitive decline.
Conclusions: The findings show that cognitive impairment in patients with Parkinson's disease is not associated with sex, but it does have a significant relationship with education and disease duration. A lack of formal education and a disease duration of more than ten years are consolidated as determining factors in cognitive impairment.
Downloads
References
1. Aarsland D, Batzu L, Halliday GM, Geurtsen GJ, Ballard C, Ray K, et al. Parkinson disease-associated cognitive impairment. Nat Rev Dis Primer [Internet]. 2021 [Citado 19/11/2024];7(1):1-21. Disponible en: https://doi.org/10.1038/s41572-021-00280-3
2. Tolosa E, Garrido A, Scholz SW, Poewe W. Challenges in the diagnosis of Parkinson’s disease. Lancet Neurol [Internet]. 2021 [Citado 19/11/2024];20(5):385-97. Disponible en: https://doi.org/10.1016/S1474-4422(21)00030-2
3. Binoy S, Lithwick A, Ben Y, Montaser L, Saban W. Online cognitive testing in Parkinson's disease: advantages and challenges. Front Neurol [Internet]. 2024 [Citado 19/11/2024];15:1363513. Disponible en: https://doi.org/10.3389/fneur.2024.136351
4. GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol [Internet]. 2019 [Citado 19/11/2024];18(5):459-80. Disponible en: https://doi.org/10.1016/S1474-4422(18)30499-X
5. Marín J, Sampedro F, Martinez S, Pagonabarraga J, Kulisevsky J. Depression as a risk factor for impulse control disorders in Parkinson disease. Ann Neurol [Internet]. 2019 [Citado 19/11/2024];86(5):762-9. Disponible en: https://doi.org/10.1002/ana.25581
6. Zhang Q, Aldridge GM, Narayanan NS, Anderson S, Uc E. Approach to cognitive impairment in Parkinson’s disease. Neurotherapeutics [Internet]. 2020 [Citado 19/11/2024];17:1495-1510. Disponible en: https://doi.org/10.1007/s13311-020-00963-x
7. Sun W, Wang Q, Yang T, Feng C, Qu Y, Yang Y, et al. A meta-analysis evaluating effects of rotigotine in Parkinson’s disease, focusing on sleep disturbances and activities of daily living. Neurol Sci [Internet]. 2022 [Citado 19/11/2024];43(10):5821-37. Disponible en: https://doi.org/10.1007/s10072-022-06159-9
8. Fabbri M, Ferreira JJ, Rascol O. COMT inhibitors in the management of Parkinson’s disease. CNS Drugs [Internet]. 2022 [Citado 19/11/2024];36(3):261-82. Disponible en: https://doi.org/10.1007/s40263-021-00888-9
9. Armstrong MJ, Rastgardani T, Gagliardi AR, Marras C. The experience of off periods: qualitative analysis of interviews with persons with Parkinson's and carepartners. Clin Park Relat Disord [Internet]. 2019 [Citado 19/11/2024];1:31-36. Disponible en: https://doi.org/10.1016/j.prdoa.2019.07.008
10. Hacker ML, Turchan M, Heusinkveld LE, Currie AD, Millan SH, Molinari AL, et al. Deep brain stimulation in early-stage Parkinson disease: five-year outcomes. Neurology [Internet]. 2020 [Citado 19/11/2024];95(4). Disponible en: https://doi.org/10.1212/WNL.0000000000009946
11. Seppi K, Ray Chaudhuri K, Coelho M. Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review. Mov Disord [Internet]. 2019 [Citado 19/11/2024];34(2):180-98. Disponible en: https://doi.org/10.1002/mds.27602
12. Hommel ALAJ, Meinders MJ, Lorenzl S, Dodel R, Coelho M, Ferreira JJ, et al. The prevalence and determinants of neuropsychiatric symptoms in late-stage Parkinsonism. Mov Disord Clin Pract [Internet]. 2020 [Citado 19/11/2024];7(5):531-42. Disponible en: https://doi.org/10.1002/mdc3.12968
13. Mills KA, Schneider RB, Saint-Hilaire M. Cognitive impairment in Parkinson's disease: associations between subjective and objective cognitive decline in a large longitudinal study. Parkinsonism Relat Disord [Internet]. 2020 [Citado 19/11/2024];80:127-32. Disponible en: https://doi.org/10.1016/j.parkreldis.2020.09.028
14. Bodel M, Kalbe E, Liepelt I. Cognition and activity of daily living function in people with Parkinson’s disease. J Neural Transm [Internet]. 2024 [Citado 19/11/2024];1-28. Disponible en: https://doi.org/10.1007/s00702-024-02796-w
15. Muñoz BE, Orozco JL. Espectro clínico y tratamiento del trastorno cognoscitivo y demencia asociada a la enfermedad de Parkinson. Acta Neurol Colomb [Internet]. 2019 [Citado 19/11/2024];35(Suppl 1):33-46. Disponible en: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S01207482019000500033&lng=en
16. Rosca E, Simu M. Parkinson’s Disease-Cognitive Rating Scale for Evaluating Cognitive Impairment in Parkinson’s Disease: A Systematic Review [Internet]. 2020 [Citado 19/11/2024];10(9):588. Disponible en: https://www.mdpi.com/2076-3425/10/9/588
17. Goetz C, Tilley B, Shaftman S, Stebbins G, Fahn S, Martínez-Martín P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results [Internet]. 2008 [Citado 19/11/2024];23:2129-70. Disponible en: https://movementdisorders.onlinelibrary.wiley.com/doi/full/10.1002/mds.22340
18. Bhidayasiri R, Tarsy D. Parkinson’s Disease: Hoehn and Yahr Scale [Internet]. 2012 [Citado 19/11/2024];4-5. Disponible en: https://link.springer.com/chapter/10.1007/978-1-60327-426-5_2
19. Aouraghe I, Khaissidi G, Mrabti M. A literature review of online handwriting analysis to detect Parkinson’s disease at an early stage. Multimedia Tools and Applications [Internet]. 2023 [Citado 19/11/2024];82(8):11923-48. Disponible en: https://www.researchgate.net/publication/363537122_A_literature_review_of_online_handwriting_analysis_to_detect_Parkinson%27s_disease_at_an_early_stage
20. Baiano C, Barone P, Trojano L, Santangelo G. Prevalence and clinical aspects of mild cognitive impairment in Parkinson's disease: a meta-analysis. Mov Disord [Internet]. 2020.[Citado 19/11/2024];35(1):45-54. Disponible en: https://doi.org/10.1002/mds.27902
21. Rosca EC, Simu M. Parkinson's disease: cognitive rating scale to assess cognitive decline in Parkinson's disease: a systematic review [Internet]. 2020 [Citado 19/11/2024];10(9):588. Disponible en: https://doi.org/10.3390/brainsci10090588
22. Vázquez LA. Deterioro cognitivo en pacientes con enfermedad de Parkinson. Acta Méd Cent [Internet]. 2021 [Citado 19/11/2024];15(2):280-7. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S2709-79272021000200280&lng=es
23. Coundouris SP, Adams AG, Grainger SA, Henry JD. Social perceptual function in Parkinson's disease: a meta-analysis. Neurosci Biobehav Rev [Internet]. 2019 [Citado 19/11/2024];104:255-67. Disponible en: https://doi.org/10.1016/j.neubiorev.2019.07.01
24. Brandão PRP, Pereira DA, Grippe TC. Parkinson's disease-cognitive rating scale (PD-CRS): normative data and mild cognitive impairment assessment in Brazil. Mov Disord Clin Pract [Internet]. 2023 [Citado 19/11/2024];10(3):452-65. Disponible en: https://doi.org/10.1002/mdc3.13657
25. Guo Y, Goetz CG, Stebbins GT, Mestre TA, Luo S. Using Movement Disorder Society Unified Parkinson's Disease Rating Scale Parts 2 and 3 simultaneously: combining the patient voice with clinician ratings. Mov Disord [Internet]. 2023 [Citado 19/11/2024];38(3):453-63. Disponible en: https://doi.org/10.1002/mds.29308
26. Asociación Madrileña de Neurología. Clasificación por estadíos de Hoehn y Yahr [Internet]. Madrid: Asociación Madrileña de Neurología; s/f [Citado 19/11/2024]. Disponible en: https://www.amn-web.com/docs/clasificacion-por-estados-de-hoehn-y-yahr.pdf
27. Tosin MHS, Goetz CG, Luo S, Choi D, Stebbins GT. Item response theory analysis of the MDS-UPDRS motor examination: tremor vs. nontremor items. Mov Disord [Internet]. 2020 [Citado 19/11/2024];35(9):1587-95. Disponible en: https://doi.org/10.1002/mds.28110
28. Gallegos M, Morgan ML, Cervigni M. 45 years of the mini-mental state examination (MMSE): a perspective from Ibero-America. Dement Neuropsychol [Internet]. 2022 [Citado 19/11/2024];16(4):384-7. Disponible en: https://doi.org/10.1590/1980-5764-DN-2021-0097
29. Alegre J, Vela L, Fernández D, Navarro V, Macías Y, Cano R. El impacto de la gravedad de la enfermedad de Parkinson en el desempeño de las actividades de la vida diaria: un estudio observacional. Rev Neurol [Internet]. 2023 [Citado 19/11/2024];76(08):249-55. Disponible en: https://doi.org/10.33588/rn.7608.2022263
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Revista Habanera de Ciencias Médicas
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All the content of this magazine is in Open Access, distributed according to the terms of the Creative Commons Attribution-Noncommercial 4.0 License that allows non-commercial use, distribution and reproduction without restrictions in any medium, provided that the primary source is duly cited.
Download PDF
